These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25860485)

  • 1. The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma.
    Guo J; Su J; He Q; Li X; Zhao Y; Gu S; Fei C; Chang C
    Hematology; 2016 Apr; 21(3):152-61. PubMed ID: 25860485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
    Gao S; Dong F; Yang P; Chen Y; Wang Y; Wang J; Shi Y; Jing H
    Ann Hematol; 2024 Jun; 103(6):1979-1987. PubMed ID: 38206369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation between Expression Patterns of CD117/CD200 in Plasma Cells and Molecular Genetic Prognostic Parameters in Multiple Myeloma].
    Wang P; Wang XD; Liu L; Chen X; Liu F; Zhao SS; Yang H; Qiu HR; Guo R; Li JY; Wu YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1415-1420. PubMed ID: 37846693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.
    Chatterjee G; Gujral S; Subramanian PG; Tembhare PR
    Indian J Hematol Blood Transfus; 2017 Sep; 33(3):303-315. PubMed ID: 28824230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
    Walker BA; Wardell CP; Murison A; Boyle EM; Begum DB; Dahir NM; Proszek PZ; Melchor L; Pawlyn C; Kaiser MF; Johnson DC; Qiang YW; Jones JR; Cairns DA; Gregory WM; Owen RG; Cook G; Drayson MT; Jackson GH; Davies FE; Morgan GJ
    Nat Commun; 2015 Apr; 6():6997. PubMed ID: 25904160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
    Stetler-Stevenson M; Paiva B; Stoolman L; Lin P; Jorgensen JL; Orfao A; Van Dongen J; Rawstron AC
    Cytometry B Clin Cytom; 2016 Jan; 90(1):26-30. PubMed ID: 25907102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival of older patients with multiple myeloma in the era of novel agents.
    Mey UJ; Leitner C; Driessen C; Cathomas R; Klingbiel D; Hitz F
    Hematol Oncol; 2016 Dec; 34(4):217-223. PubMed ID: 25898820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloma cell-derived Runx2 promotes myeloma progression in bone.
    Trotter TN; Li M; Pan Q; Peker D; Rowan PD; Li J; Zhan F; Suva LJ; Javed A; Yang Y
    Blood; 2015 Jun; 125(23):3598-608. PubMed ID: 25862559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
    Blommestein HM; Verelst SG; de Groot S; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    Eur J Haematol; 2016 Feb; 96(2):198-208. PubMed ID: 25892333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
    Schey S; Brown SR; Tillotson AL; Yong K; Williams C; Davies F; Morgan G; Cavenagh J; Cook G; Cook M; Orti G; Morris C; Sherratt D; Flanagan L; Gregory W; Cavet J;
    Br J Haematol; 2015 Aug; 170(3):336-48. PubMed ID: 25891006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
    Sehgal K; Das R; Zhang L; Verma R; Deng Y; Kocoglu M; Vasquez J; Koduru S; Ren Y; Wang M; Couto S; Breider M; Hansel D; Seropian S; Cooper D; Thakurta A; Yao X; Dhodapkar KM; Dhodapkar MV
    Blood; 2015 Jun; 125(26):4042-51. PubMed ID: 25869284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.
    Musto P; Simeon V; Grossi A; Gay F; Bringhen S; Larocca A; Guariglia R; Pietrantuono G; Villani O; D'Arena G; Cuomo C; Musto C; Morabito F; Petrucci MT; Offidani M; Zamagni E; Tacchetti P; Conticello C; Milone G; Palumbo A; Cavo M; Boccadoro M
    Stem Cell Res Ther; 2015 Apr; 6(1):64. PubMed ID: 25889496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
    Laubach JP; Richardson PG
    Clin Cancer Res; 2015 Jun; 21(12):2660-2. PubMed ID: 25878332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data.
    Sevcikova S; Paszekova H; Besse L; Sedlarikova L; Kubaczkova V; Almasi M; Pour L; Hajek R
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Jun; 159(2):288-93. PubMed ID: 25877407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term control in a patient with refractory multiple myeloma by oral cyclophosphamide and dexamethasone.
    Steiner N; Nachbaur D; König P; Willenbacher W; Gunsilius E
    Anticancer Res; 2015 Apr; 35(4):2165-8. PubMed ID: 25862873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
    Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
    Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
    Guillerey C; Ferrari de Andrade L; Vuckovic S; Miles K; Ngiow SF; Yong MC; Teng MW; Colonna M; Ritchie DS; Chesi M; Bergsagel PL; Hill GR; Smyth MJ; Martinet L
    J Clin Invest; 2015 May; 125(5):2077-89. PubMed ID: 25893601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
    Bolomsky A; Hose D; Schreder M; Seckinger A; Lipp S; Klein B; Heintel D; Ludwig H; Zojer N
    J Hematol Oncol; 2015 Feb; 8():10. PubMed ID: 25887188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.
    Cho Y; Hori M; Okoshi Y; Fujisawa F; Shinagawa A; Kudo D; Komeno T; Yoshida C; Katsura Y; Ota I; Shimizu S; Kamoshita M; Sasaki K; Tanaka K; Mukai HY; Kojima H
    Acta Haematol; 2015; 134(1):25-31. PubMed ID: 25871926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagic Markers BECLIN 1 and LC3 are Associated with Prognosis of Multiple Myeloma.
    Jung G; Roh J; Lee H; Gil M; Yoon DH; Suh C; Jang S; Park CJ; Huh J; Park CS
    Acta Haematol; 2015; 134(1):17-24. PubMed ID: 25871810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.